# A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

> **NCT06385522** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Boston Immune Technologies and Therapeutics** · enrollment: 37 (estimated)

## Conditions studied

- NHL
- Cutaneous T Cell Lymphoma
- Peripheral T-cell Lymphoma

## Interventions

- **BIOLOGICAL:** BITR2101

## Key facts

- **NCT ID:** NCT06385522
- **Lead sponsor:** Boston Immune Technologies and Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2026-06
- **Final completion:** 2027-02
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06385522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06385522, "A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06385522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*